Finance

Lists
LILY34:BVMF
Eli Lilly And Company BDR
R$205,49
-0,56%
(-1,16) 1D
30 ກ.ຍ., 10 ໂມງ 54 ນາທີ 55 ວິນາທີ GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for LILY34...
Open
R$206,65
High
R$206,65
Low
R$204,14
Mkt. cap
1,12 ລ້ານລ້ານ
Avg. vol.
38,66 ພັນ
Volume
1,52 ພັນ
52-wk high
R$223,07
52-wk low
R$133,92
Shares outstanding
941,36 ລ້ານ
No. of employees
50 ພັນ
Open
R$206,65
High
R$206,65
Low
R$204,14
Mkt. cap
1,12 ລ້ານລ້ານ
Avg. vol.
38,66 ພັນ
Volume
1,52 ພັນ
52-wk high
R$223,07
52-wk low
R$133,92
Shares outstanding
941,36 ລ້ານ
No. of employees
50 ພັນ
News stories
From web sources and news partners
Yahoo! Finance Canada
Yahoo! Finance Canada
·
1 ຊົ່ວໂມງກ່ອນ
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
Investing.com Canada
Investing.com Canada
·
1 ຊົ່ວໂມງກ່ອນ
Lilly’s Ebglyss shows efficacy in hand, foot dermatitis trial By Investing.com
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Company BDR
CEODavid A. Ricks
Employees50 ພັນ
Founded1876
Headquartersອິນເດຍນາໂພລິສ, ອິນເດຍນາ, ສະຫະລັດ
SectorPharmaceutical industry
Websitelilly.com
Last report
5 ສ.ຫ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
US$8,38 / US$6,58
+27,27%beat
Revenue / Est. (USD)
22,97 ຕື້ / 20,69 ຕື້
+11,06%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
17,60 ຕື້
19,29 ຕື້
19,80 ຕື້
22,97 ຕື້
Cost of goods sold
3,01 ຕື້
3,37 ຕື້
3,58 ຕື້
3,27 ຕື້
Cost of revenue
3,01 ຕື້
3,37 ຕື້
3,58 ຕື້
3,27 ຕື້
Research and development expenses
3,47 ຕື້
3,80 ຕື້
3,51 ຕື້
3,82 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,63 ຕື້
3,46 ຕື້
2,93 ຕື້
3,43 ຕື້
Operating expense
6,09 ຕື້
7,26 ຕື້
6,44 ຕື້
7,25 ຕື້
Total operating expenses
9,10 ຕື້
10,63 ຕື້
10,02 ຕື້
10,52 ຕື້
Operating income
8,50 ຕື້
8,66 ຕື້
9,78 ຕື້
12,46 ຕື້
Other non operating income
-9,10 ລ້ານ
181,20 ລ້ານ
170,00 ລ້ານ
561,00 ລ້ານ
EBT including unusual items
7,23 ຕື້
8,27 ຕື້
8,85 ຕື້
9,25 ຕື້
EBT excluding unusual items
8,21 ຕື້
8,89 ຕື້
9,71 ຕື້
12,73 ຕື້
Income tax expense
1,65 ຕື້
1,63 ຕື້
1,45 ຕື້
2,15 ຕື້
Effective tax rate
22,81%
19,70%
16,43%
23,27%
Other operating expenses
-
-
-
-
Net income
5,58 ຕື້
6,64 ຕື້
7,40 ຕື້
7,10 ຕື້
Net profit margin
31,72%
34,41%
37,36%
30,88%
Earnings per share
7,02
7,54
8,55
8,38
Interest and investment income
65,00 ລ້ານ
672,40 ລ້ານ
-
-
Interest expense
-179,60 ລ້ານ
-153,30 ລ້ານ
-332,00 ລ້ານ
-345,00 ລ້ານ
Net interest expenses
-114,60 ລ້ານ
519,10 ລ້ານ
-332,00 ລ້ານ
-345,00 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
8,97 ຕື້
9,25 ຕື້
10,29 ຕື້
12,99 ຕື້
Gain or loss from assets sale
-
-180,00 ລ້ານ
-
-
AI content may include mistakes. Learn more
ແອັບຂອງ Google